NO955167L - Monoklonalt anti-V-integrin-antistoff - Google Patents

Monoklonalt anti-V-integrin-antistoff

Info

Publication number
NO955167L
NO955167L NO955167A NO955167A NO955167L NO 955167 L NO955167 L NO 955167L NO 955167 A NO955167 A NO 955167A NO 955167 A NO955167 A NO 955167A NO 955167 L NO955167 L NO 955167L
Authority
NO
Norway
Prior art keywords
monoclonal anti
integrin antibody
integrin
antibody
monoclonal
Prior art date
Application number
NO955167A
Other languages
English (en)
Other versions
NO955167D0 (no
NO321186B1 (no
Inventor
Francesc Mitjans
Jaume Piulats
Elisabet Rosell
Jaume Adan
Simon Goodman
Diane Sander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO955167(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO955167D0 publication Critical patent/NO955167D0/no
Publication of NO955167L publication Critical patent/NO955167L/no
Publication of NO321186B1 publication Critical patent/NO321186B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19955167A 1994-12-20 1995-12-19 Monoklonale anti-alfa-V-integrin-antistoffer, antistoffragmenter av disse, hybridomcellelinje som produserer dem, aminosyresekvenser som utgjor dem, DNA-sekvenser som koder for aminosyresekvensene, farmasoytisk preparat som omfatter antistoffene og antistoffragmentene, fremgangsmate for fremstilling av antistoffene og antistoffragmentene og anvendelse av antistoffene og antistoffragmentene for fremstilling av legemidler og diagnostiske forbindelser. NO321186B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (3)

Publication Number Publication Date
NO955167D0 NO955167D0 (no) 1995-12-19
NO955167L true NO955167L (no) 1996-06-21
NO321186B1 NO321186B1 (no) 2006-04-03

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955167A NO321186B1 (no) 1994-12-20 1995-12-19 Monoklonale anti-alfa-V-integrin-antistoffer, antistoffragmenter av disse, hybridomcellelinje som produserer dem, aminosyresekvenser som utgjor dem, DNA-sekvenser som koder for aminosyresekvensene, farmasoytisk preparat som omfatter antistoffene og antistoffragmentene, fremgangsmate for fremstilling av antistoffene og antistoffragmentene og anvendelse av antistoffene og antistoffragmentene for fremstilling av legemidler og diagnostiske forbindelser.

Country Status (26)

Country Link
US (1) US5985278A (no)
EP (1) EP0719859B1 (no)
JP (1) JP3898245B2 (no)
KR (1) KR100450368B1 (no)
CN (1) CN1117763C (no)
AR (1) AR001778A1 (no)
AT (1) ATE244306T1 (no)
AU (1) AU710234B2 (no)
BR (1) BR9505980B1 (no)
CA (1) CA2165573C (no)
CO (1) CO4480042A1 (no)
CZ (1) CZ290477B6 (no)
DE (1) DE69531187T2 (no)
DK (1) DK0719859T3 (no)
ES (1) ES2202336T3 (no)
FI (1) FI118536B (no)
HU (1) HU221061B1 (no)
NO (1) NO321186B1 (no)
PL (1) PL182961B1 (no)
PT (1) PT719859E (no)
RU (1) RU2205223C2 (no)
SI (1) SI0719859T1 (no)
SK (1) SK284932B6 (no)
TR (1) TR199501614A2 (no)
UA (1) UA40621C2 (no)
ZA (1) ZA9510806B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
EP0996460B1 (en) * 1997-08-08 2005-01-12 The Regents of the University of California Treatment of kidney fibrosis with antibodies against integrin alpha-v-beta 6
DE69930723T2 (de) * 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
EP1414491A4 (en) * 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US8940683B2 (en) 2006-08-10 2015-01-27 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
EP2526967A1 (en) 2007-07-17 2012-11-28 Merck Patent GmbH Engineered anti-alpha v-integrin hybrid antibodies
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CA2747937C (en) 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
AU2010318323A1 (en) 2009-11-13 2012-06-28 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
SG183356A1 (en) * 2010-02-18 2012-09-27 Univ California INTEGRIN aVß8 NEUTRALIZING ANTIBODY
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
EP3501546A3 (de) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
BR112014003501B1 (pt) * 2011-08-17 2022-02-08 The Regents Of The University Of California Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
HK1254295A1 (zh) 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
CN113993896A (zh) * 2019-04-08 2022-01-28 比奥根Ma公司 抗整联蛋白抗体及其用途
EP4058481A1 (en) 2019-11-15 2022-09-21 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
EP4305072A4 (en) * 2021-03-09 2025-06-18 The Governing Council Of The University Of Toronto ANTIBODIES AGAINST INTEGRIN HETERODIMERS AND THEIR USES
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
DE69531187D1 (de) 2003-08-07
CZ328895A3 (en) 1996-09-11
HU9503638D0 (en) 1996-02-28
CA2165573A1 (en) 1996-06-21
PL182961B1 (pl) 2002-05-31
TR199501614A2 (tr) 1996-07-21
US5985278A (en) 1999-11-16
SK284932B6 (sk) 2006-02-02
SK159295A3 (en) 1996-07-03
AU710234B2 (en) 1999-09-16
CZ290477B6 (cs) 2002-07-17
NO955167D0 (no) 1995-12-19
UA40621C2 (uk) 2001-08-15
CN1139115A (zh) 1997-01-01
PT719859E (pt) 2003-11-28
EP0719859B1 (en) 2003-07-02
SI0719859T1 (en) 2003-12-31
KR100450368B1 (ko) 2005-01-31
HU221061B1 (hu) 2002-07-29
CN1117763C (zh) 2003-08-13
JP3898245B2 (ja) 2007-03-28
BR9505980B1 (pt) 2010-02-23
NO321186B1 (no) 2006-04-03
PL311926A1 (en) 1996-06-24
HUT74828A (en) 1997-02-28
KR960022562A (ko) 1996-07-18
BR9505980A (pt) 1997-12-23
ES2202336T3 (es) 2004-04-01
DK0719859T3 (da) 2003-10-20
JPH08231597A (ja) 1996-09-10
DE69531187T2 (de) 2004-04-22
ZA9510806B (en) 1996-05-30
EP0719859A1 (en) 1996-07-03
FI956112L (fi) 1996-06-21
FI956112A0 (fi) 1995-12-19
CO4480042A1 (es) 1997-07-09
FI118536B (fi) 2007-12-14
RU2205223C2 (ru) 2003-05-27
ATE244306T1 (de) 2003-07-15
AR001778A1 (es) 1997-12-10
CA2165573C (en) 2011-03-29
AU4042195A (en) 1996-06-27

Similar Documents

Publication Publication Date Title
FI956112A0 (fi) Monoklonaalinen anti- V-integriinivasta-aine
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
FI963004A7 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI965032L (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
FI960567A7 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
FI945485L (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
DE69324928D1 (de) Monoklonaler antikörper
BR1100555B1 (pt) anticorpos monoclonais humanizados.
FI963901L (fi) Tie-reseptoria tunnistavat monoklonaaliset vasta-aineet ja niiden käyttö
NO20000079D0 (no) Ancrod spesifikke monoklonale antistoff, antistoff- fragmenter, blandinger, derivater og anvendelse derav
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees